Introduction
Lamotrigine (LTG) is only available commercially as oral formulations. Intravenous (IV) formulations are useful when treating patients where oral administration is not possible and to study certain pharmacokinetic parameters such as bioavailability. We developed a formulation of LTG with a 25% 2-hydroxylpropyl-b-cylodextrin as the vehicle for the purpose of exploring steady state elimination. Clinically an intravenous formulation of LTG could be useful for short term replacement dosing when patients have an interruption in their oral route of administration for reasons such as surgery or vomiting. For research purposes, the incorporation of a stable-label (SL) into the LTG molecule permitted the analytical differentiation between orally administered LTG (unlabeled) from that LTG administered intravenously (SL) by gas chromatography-mass spectrometry and enabled study of pharmacokinetics at steady state dosing. In this report we discuss the safety and tolerability of an intravenous LTG formulation given as a small tracer dose to patients who are currently receiving LTG for clinical reasons.
Methods

Subjects
This study was performed at the University of Minnesota and Emory University. The Institutional Review Board Human Subject's Committees at all sites approved this study. All patients and/or guardians provided consent. Adult patients (18-63 years) who were already on a steady-state dose of LTG were enrolled into the study. Patients with significant cardiovascular disease that might prevent them from tolerating an intravenous infusion or who were receiving any medications that might affect LTG pharmacokinetics were excluded.
Formulation
This SL-LTG formulation was approved by the FDA for research purposes (IND # 72,642). Purpose: Intravenous (IV) formulations are useful when treating patients where oral administration is not possible and to study certain pharmacokinetic parameters such as bioavailability. We developed a stable-labeled IV formulation of lamotrigine (LTG) for studying pharmacokinetics in epilepsy patients. Methods: Stable-labeled IV LTG was given to 20 persons with epilepsy (6 men; 14 women) with a mean age of 34.8 years (SD 11.7). A 50 mg dose of LTG (stable labeled) was given intravenously and replaced 50 mg of the regular morning oral dose of LTG (unlabeled, commercially available formulation).
Results: No significant changes in blood pressure, heart rate, or adverse events including rash were attributed to administration of a 50-mg dose of the intravenous LTG formulation. Conclusion: Our results show that LTG base that is complexed with 2-hydroxypropyl-b-cyclodextrin and stable-labeled can be given safely as a tracer replacement dose. ß 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
solution to make a final strength of 10 mg/mL by the Pharmaceutics Division at the University of Iowa. The formulation was dispensed into 5 mL single use ampoules.
Study design
Subjects were admitted to a research center and were under medical supervision for a minimum of 8 h. A normal saline infusion was started at 50 ml/h prior to and maintained for 30 min after the infusion. A single 50 mg dose of SL-LTG was administered undiluted IV over 15 min at a rate of 0.33 ml/min with a syringe pump. After the infusion was complete, each subject took his/her usual maintenance morning oral LTG dose less 50 mg followed by the remainder of their daily dose at the normally prescribed time. A physician assessed each subject via a brief neurological exam before and after each intravenous SL-LTG administration. The infusion site was inspected for signs of inflammation throughout the study. Patients were asked during the infusion if they were experiencing discomfort at the infusion site or any other symptoms. A 3-lead electrocardiogram (ECG) was obtained prior to, during, and immediately after the infusion. Blood pressure (BP) and heart rate (HR) were measured prior to, every 2 min during, then every 15 min (for the first hour) following completion of the infusion. Early study termination points were an AV block (PR interval greater than 200 ms), bradycardia less than 50 beats per minute (unless baseline is less than 50), emergence of any arrhythmia not present at baseline, or if systolic or diastolic BP changed by more than 30 mmHg from baseline during the infusion.
The percent change of BP and HR were calculated for two periods: period 1 (pre-infusion to end of infusion) and period 2 (30-min post-infusion to end of infusion). Statistical analysis included a paired t-test comparing the two periods (SPSS Version 20.0). A p value of <0.05 was considered significant.
Results
Twenty (6 men/14 women; 1 African American/19 Caucasians) subjects were enrolled and completed the study. The mean age was 34.8 years (SD = 11.7, range 18-63 years). The mean weight was 72.1 kg (SD = 17.3, range 48.3-117.3 kg). The mean maintenance LTG dose was 463.8 mg (range 200-800 mg). Complete BP and HR data were available for 18 subjects. One subject was missing a baseline BP measurement and another subject was missing a HR measurement at the end of infusion. The infusion was well tolerated and no infusions were discontinued due to safety concerns.
There were no statistical differences in the percent change from baseline to end of infusion or from baseline to 30 min post infusion for systolic or diastolic blood pressure or heart rate. (Table 1 ). There were no drug related adverse events. Rash was not observed although one subject had some redness around the infusion site; however, it was concluded to be due to irritation from the IV infusion needle. A second person reported a feeling of chest tightness. The ECG was normal and the tightness resolved quickly. This subject had reported nasal congestion and pre-syncopal symptoms prior to the infusion.
Discussion
This is the first report on the safety of a cyclodextrin-based intravenous LTG formulation given to humans. Most AEDs are approved as oral solid formulations due to their insolubility or lack of commercial interest in developing an intravenous formulation. The use of intravenous stable isotope labeled formulations can aid in pharmacokinetic studies especially when studying medications used in therapeutic areas such as epilepsy where chronic therapy cannot be interrupted for clinical and ethical reasons. For clinical purposes, the availability of intravenous formulations may be useful as short term replacement therapy. Our group has developed stable-labeled intravenous formulations of various AEDs (fosphenytoin, phenytoin, carbamazepine, valproic acid and topiramate) for studies evaluating the effect of age on pharmacokinetics and absolute bioavailability. [1] [2] [3] [4] [5] Currently, two of these products (intravenous carbamazepine and topiramate) are being investigated for clinical use. Whereas some AEDs, such as valproic acid have good water solubility and commercially available parenteral solutions, others do not. Only one report exists that describes LTG given to eight healthy volunteers via intravenous administration. Yuen and Peck reported the pharmacokinetics of LTG after administration of a water-soluble LTG salt (LTG isethionate) with 4% dextrose infused over 30 min. 6 Both the oral and intravenous formulations used in this study were reported to have no adverse events or changes in vital signs; however, no safety data were presented. Inclusion complexes of water insoluble drugs with cyclodextrins can improve the solubility profile of a drug and enable the creation of an oral solution or intravenous formulation. 7 Previous reports with LTG cyclodextrin complexes explored the feasibility of cyclodextrin as an excipient to improve pharmacokinetic characteristics in solid dosage formulations, 8, 9 but not possible intravenous formulations. Remmel and Sinz previously evaluated the pharmacokinetics and metabolism of IV LTG in guinea pigs with a hydroxypropyl-b-cyclodextrin formulation. 10 A possible limitation of this formulation is the risk of rash or more severe allergic reactions such as Stevens-Johnson syndrome. The risk of rash from LTG increases with higher doses and faster titration rates. 11 Due to a higher bioavailability of an intravenous over an oral formulation it is possible that patients who are already receiving LTG orally may be at higher risk of rash due to higher concentrations of drug delivered directly to the circulatory system via the intravenous route. The absolute bioavailability of a single 75 mg dose of the water-soluble intravenous formulation was 98 AE 0.05% indicating that there may be little difference in drug concentrations compared to the oral formulation. 6 There were no signs of rash in our study in patients on a 50 mg LTG steady state dose. Studies at higher intravenous doses are needed to assess the clinical utility of the formulation and the risk of adverse events.
To the best of our knowledge, this is the first report of LTG complexed with 2-hydroxypropyl-b-cyclodextrin intravenously being administered to patients. Our results show that LTG base that is complexed with 2-hydroxypropyl-b-cyclodextrin and stablelabeled can be given safely as a tracer replacement dose. These results are similar to those observed with a study dose of stablelabel-cyclodextrin complexed carbamazepine. 12 A limitation of this report is the relatively small sample size. Additional studies with larger doses are needed in order to determine the utility of this formulation as a full dose replacement for bridge therapy when delivering medications orally is not possible.
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